Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

editorial-team@simplywallst.com (Simply Wall St)

Tue, Mar 4, 2025, 1:52 PM 1 min read

Neuren Pharmaceuticals (ASX:NEU) Full Year 2024 Results

Key Financial Results

Revenue: AU$216.8m (down 6.5% from FY 2023).
Net income: AU$142.0m (down 9.6% from FY 2023).
Profit margin: 66% (down from 68% in FY 2023).
EPS: AU$1.11 (down from AU$1.24 in FY 2023).

revenue-and-expenses-breakdown — ASX:NEU Revenue and Expenses Breakdown March 4th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neuren Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 21%.

In the last 12 months, the only revenue segment was Commercial Products contributing AU$213.2m. The most substantial expense, totaling AU$37.1m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how NEU's revenue and expenses shape its earnings.

Looking ahead, revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Australia are expected to grow by 44%.

Performance of the Australian Pharmaceuticals industry.

The company's shares are down 7.9% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Neuren Pharmaceuticals that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.